ImmunityBio, Inc. (IBRX) earnings
IBRX earnings moved a median of -0.51% by the close. Quarterly and annual IBRX reports and results, each read against the price at its own news timestamp. Back to the IBRX overview →
15 measured IBRX earnings events.
Where these IBRX earnings landedvs 15 measured IBRX earnings reactions
| Middle 50% of IBRX earnings reactions | -4.74% to +2.78% |
|---|---|
| Median reaction (to close) | -0.51% |
| Measured reactions | 15 |
Point-in-time · zero look-ahead
Half of the 15 IBRX earnings events with a measured close landed between -4.74% and +2.78%; 47% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q ImmunityBio, Inc. For: Jun 30 | SEC filing · Form 10-Q | +6.20% | +2.51% | |
| Form 10-Q ImmunityBio, Inc. For: Mar 31 | SEC filing · Form 10-Q | +1.73% | -0.51% | |
| ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million | Press release | +1.73% | -0.51% | |
| Form 10-K ImmunityBio, Inc. For: Dec 31 | SEC filing · Form 10-K | -0.74% | +13.68% | |
| Form 10-Q ImmunityBio, Inc. For: Sep 30 | SEC filing · Form 10-Q | -2.74% | -1.83% | |
| Form 10-Q ImmunityBio, Inc. For: Jun 30 | SEC filing · Form 10-Q | -0.21% | +0.42% | |
| ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code | Press release | -0.21% | +0.42% | |
| Form 10-Q ImmunityBio, Inc. For: Mar 31 | SEC filing · Form 10-Q | +6.09% | +5.36% | |
| Form 10-K ImmunityBio, Inc. For: Dec 31 | SEC filing · Form 10-K | -0.31% | -12.31% | |
| Form 10-Q ImmunityBio, Inc. For: Sep 30 | SEC filing · Form 10-Q | -3.36% | -7.65% | |
| ImmunityBio Reports Third-Quarter 2024 Financial Results | Press release | -3.36% | -7.65% | |
| Form 10-Q ImmunityBio, Inc. For: Jun 30 | SEC filing · Form 10-Q | +1.78% | -1.56% | |
| Form 10-Q ImmunityBio, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.47% | +3.05% | |
| Form 10-K ImmunityBio, Inc. For: Dec 31 | SEC filing · Form 10-K | +4.55% | +8.91% | |
| Form 10-Q ImmunityBio, Inc. For: Sep 30 | SEC filing · Form 10-Q | -1.49% | -15.07% |
Keep exploring
More IBRX: analyst actions → · SEC filings → · IBRX overview →